- Home
- PGNY
PGNY
Progyny Inc.
as 11-20-2024 4:00pm EST
Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 1.5B | IPO Year: | 2019 |
| Target Price: | $20.00 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.60 | EPS Growth: | 17.45 |
| 52 Week Low/High: | $13.39 - $42.08 | Next Earning Date: | 11-12-2024 |
| Revenue: | $1,138,730,000 | Revenue Growth: | 10.24% |
| Revenue Growth (this year): | 9.77% | Revenue Growth (next year): | 1.76% |
Latest Progyny Inc. News
PGNY Breaking Stock News: Dive into PGNY Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
Here’s Why Progyny (PGNY) Was Under Pressure in Q3
GlobeNewswire
7 days ago
Progyny, Inc. to Present at Jefferies London Healthcare Conference
Simply Wall St.
7 days ago
Progyny Third Quarter 2024 Earnings: Misses Expectations
TipRanks
7 days ago
Progyny price target lowered to $21 from $22 at BofA
Motley Fool
8 days ago
Why Progyny Stock Crashed Today
MT Newswires
8 days ago
Jefferies Adjusts Progyny Price Target to $19 From $24, Maintains Buy Rating
MT Newswires
8 days ago
Sector Update: Health Care Stocks Rise Premarket Wednesday
MT Newswires
8 days ago
Sector Update: Health Care
Compare PGNY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PGNY Progyny Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.